Utpal Koppikar

Utpal Koppikar, MBA, has served as a member of the Board of Directors since March 2022. Utpal is currently the Chief Financial Officer of Atara Biotherapeutics, a leader in T-cell immunotherapy that is leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases. At Atara, he oversees the finance, information technology, and investor relations functions as well as guiding the company’s strategy as a member of the senior leadership team. Prior to his tenure with Atara, Utpal held several senior financial leadership positions at Gilead Sciences, including Vice President of Corporate and Operations Finance. During his time there, he led the three-year financial planning process and financial integration of Kite Pharma and played a key role as Gilead’s Vice President of Finance Europe, Middle East, and Australia in the launch of multiple HIV and HCV product launches. Prior to joining Gilead, Utpal served in multiple finance roles of increasing responsibility at Amgen. Utpal previously served as a board member of Flexion Therapeutics Inc. until its sale to Pacira Biosciences Inc. in November 2021. He holds a B.S. in aerospace engineering from the University of Maryland, an M.S. in aeronautical engineering from Stanford University, and an MBA in finance from UCLA’s Anderson School of Management.